JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

Inicio・Lista de Acciones・Eli Lilly and Co.

Eli Lilly and Co.

Cerrado

SectorSanidad

1,066.82 2.48

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1056.05

Máximo

1070.02

Métricas clave
By Trading Economics
Ingresos	758M 7.4B
Ventas	507M 20B
P/B Media del Sector	35.088 49.701
BPA	8.55
Rentabilidad por dividendo	0.62
Margen de beneficios	37.355
Empleados	50,000
EBITDA	971M 9.4B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+18.99% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	0.62% 2.39%
Próximas Ganancias	5 ago 2026
Fecha Próximo Dividendo	10 jun 2026
Próxima Fecha de Ex Dividendo	14 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	105B 881B
Apertura anterior	1064.34
Cierre anterior	1066.82

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

129 / 345 Clasificación en Healthcare

Eli Lilly and Co. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 may 2026, 14:24 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly Buys Engage Biologics for Up to $202 Million

30 abr 2026, 12:01 UTC

Ganancias

Principales Movimientos del Mercado

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

20 may 2026, 13:35 UTC

Adquisiciones, fusiones, absorciones

Engage Bio: Eli Lilly Deal Includes Upfront, Milestone Payments >LLY

20 may 2026, 13:34 UTC

Adquisiciones, fusiones, absorciones

Engage Bio Acquired by Eli Lilly for Up to $202 Million >LLY

7 may 2026, 09:30 UTC

Ganancias

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 may 2026, 12:36 UTC

Ganancias

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 may 2026, 10:12 UTC

Ganancias

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 may 2026, 09:58 UTC

Ganancias

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30 abr 2026, 20:59 UTC

Acciones populares

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30 abr 2026, 20:12 UTC

Ganancias

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 abr 2026, 16:43 UTC

Ganancias

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30 abr 2026, 16:10 UTC

Charlas de Mercado

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30 abr 2026, 15:13 UTC

Ganancias

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 abr 2026, 14:58 UTC

Ganancias

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30 abr 2026, 14:53 UTC

Ganancias

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30 abr 2026, 14:50 UTC

Ganancias

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30 abr 2026, 14:42 UTC

Ganancias

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30 abr 2026, 14:39 UTC

Ganancias

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30 abr 2026, 14:35 UTC

Ganancias

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30 abr 2026, 14:24 UTC

Ganancias

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30 abr 2026, 14:17 UTC

Ganancias

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30 abr 2026, 13:56 UTC

Ganancias

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 abr 2026, 13:37 UTC

Acciones populares

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 abr 2026, 12:32 UTC

Charlas de Mercado

Ganancias

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

30 abr 2026, 12:29 UTC

Charlas de Mercado

Ganancias

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

30 abr 2026, 12:23 UTC

Charlas de Mercado

Ganancias

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

30 abr 2026, 12:10 UTC

Ganancias

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 abr 2026, 12:08 UTC

Ganancias

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

30 abr 2026, 12:04 UTC

Charlas de Mercado

Ganancias

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

30 abr 2026, 11:39 UTC

Acciones populares

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

Comparación entre iguales

Cambio de precio

Eli Lilly and Co. previsión

Precio Objetivo

By TipRanks

18.99% repunte

Estimación a 12 Meses

Media 1,267.24 USD 18.99%

Máximo 1,500 USD

Mínimo 850 USD

De acuerdo con 23 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Eli Lilly and Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

23 ratings

Comprar

Mantener

Vender

De acuerdo con 23 analistas que ofrecen calificaciones bursátiles a para Eli Lilly and Co. Dist en los últimos 3 meses.

Sentimiento

By Acuity

129 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.